CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.

By Castellano, Daniel. European urology, 2015 . 68(4):621-9. , Formato Vancouver: Diekstra MH, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH et al. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol. 2015 Oct;68(4):621-9.

Place Hold on CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.

Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.

By Castellano, Daniel. European urology, 2015 . 67(5):904-12. , Fórmato Vancouver: Fizazi K, Abrahamsson PA, Ahlgren G, Bellmunt J, Castellano D, Culine S et al. Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol. 2015 May;67(5):904-12.

Place Hold on Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.

Search for 'Provider:European urology,'

CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.

Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe.